Fosinopril is an effective antihypertensive " , , Fosinopril gil'en once daily, alone or with a

diuretic, safely and effectil'ely controls blood pressure in patients with mild-to-moderate essential hypertension.'

After a 4-week placebo phase, 220 evaluable patients randomly received fosinopril 10, 40 or 80mg, or placebo once-daily for 4 weeks. Treatment was continued for a further 4 weeks, with chlorthalidone 25 mg/day added if required to further control BP.

By week 4, diastolic BP had decreased by 6% with placebo, and by 9, 11.5, and 12.5% with fosinopril 10, 40 and 80mg, respectively. Systolic and diastolic BP values were significantly lower in patients receiving fosinopril 40 or 80mg compared with patients receiving fosinopril IOmg or placebo. Chlorthalidone was required by 54% of placebo recipients, and by 59, 42 and 43% of fosinopril 10, 40, and 80mg recipients, respectively. A further reduction in BP was observed in all chlorthalidone recipients.

The most commonly reported adverse effects were lightheadedness, dizziness, cough and gastrointestinal disorders.

At the conclusion of the trial, 148 patients elected to enter an open tria! of fosinopri! with BP levels remaining relatively constant for 10-13 months' follow-up. Adverse effects were reported by 24% of these patients. Anderson RJ . Duchin KL. Gore RD. Herman TS. Michaels RS. ct al. Once-daily fosinopril in the treatment of h ypenension. Hypcnension 17: 636-642. May 1991 "'"

ISSN 0156-2703/91/0706-0015/0$01.00/0 <D Adis International Ltd 15

INPHARMA®6 lui 1991